Alumis and ACELYRIN Announce Strategic Merger Proposal
Stockholders are set to reap significant benefits from a newly proposed merger between Alumis Inc. and ACELYRIN, INC. This strategic alliance aims to create a robust late-stage biopharmaceutical company dedicated to developing innovative therapies targeting immune-mediated diseases.
Unanimous Board Recommendations
Both companies' boards have unanimously recommended that stockholders vote in favor of the merger. This merger is not just a choice but a strategic alignment that aims to maximize shareholder value. With expectations for the merger to close in the second quarter of the year following the upcoming Special Meetings of Stockholders, it promises to lay a strong foundation for the future of both entities.
The Benefits of Merging
The merger proposal holds vast potential for both companies, leveraging their respective strengths. Alumis' clinical stage pipelines, designed to provide personalized treatments, and ACELYRIN's focus on transformative medicines positions the combined entity uniquely in the market.
Highlighting the Combined Strengths
One key aspect of the merger is the robust clinical portfolio that will emerge as a result. The consolidation will also lead to improved financial synergies and a focus on innovative therapeutics. With a combined cash reserve of around $737 million, the new entity is anticipated to have the financial flexibility to navigate through key clinical trials and product launches anticipated in the coming years. This financial runway is expected to support programs well into the future, particularly beyond 2026.
Upcoming Milestones
Both companies have exciting clinical trials on the horizon. Alumis' ESK-001, which is a candidate for treating moderate-to-severe plaque psoriasis, will have pivotal reads coming up in 1Q 2026. Additionally, the Phase 2b LUMUS trial for systemic lupus erythematosus is projected for exciting data release in 2026. As part of the merger, they will also kick off a clinical trial for A-005, aimed at treating multiple sclerosis, along with the potential development of lonigutamab for thyroid eye disease.
Strong Leadership and Vision
The combined company will benefit from a world-class leadership team, bringing extensive experience in the biopharmaceutical industry. The focus on a capital-efficient operating model is expected to enhance operational efficacy. The intention behind this merger is not merely financial; it’s about creating a cohesive entity that drives the development of next-generation treatments for patients who need them the most.
Voting and Next Steps
The upcoming Special Meetings of Stockholders, slated for May 13, 2025, will be crucial for both companies. Stockholders will have the opportunity to vote on this transformative merger, which offers an exchange of 0.4274 shares of Alumis common stock for each share owned of ACELYRIN. This approach signifies a fair valuation for stockholders from both firms and reflects the anticipated future growth as a united entity.
Contact details for both companies are provided for stockholders needing assistance regarding the meetings or where to obtain proxy materials. Alumis can be reached through MacKenzie Partners, while ACELYRIN stockholders can consult Sodali & Co for guidance, ensuring a transparent process.
Conclusion
This merger not only symbolizes a groundbreaking step in the biopharmaceutical landscape but also points toward a collaborative future focused on innovation and treatment advancements. As the industry continues to evolve, the combination of Alumis and ACELYRIN holds the promise of delivering groundbreaking therapies that can change lives.
Frequently Asked Questions
What is the purpose of the merger between Alumis and ACELYRIN?
The merger aims to create a stronger biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases.
When is the special stockholder meeting scheduled?
The special meeting for stockholders will take place on May 13, 2025, where they will vote on the proposed merger.
What will the stockholders receive in the merger?
ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each ACELYRIN share owned.
How will this merger impact the clinical pipeline?
The merger is expected to enhance the combined clinical pipeline, including ongoing trials and new opportunities for drug development.
Who should stockholders contact for more information?
Stockholders can reach out to Alumis’ proxy solicitors at MacKenzie Partners or ACELYRIN’s at Sodali & Co for any assistance related to the merger process.
